Replies to post #594707 on NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

rizona,

Was thinking the same. Question is, vetted by whom, regulator(s), pre submission advisors or both on a rolling basis? Seems to me it’s probably both and that review after final will be expedited. Best wishes.

[pgsd]

Difficult to know for sure but interesting as the two Doctors were involved in the trial so perhaps they have more insight ?

The study – conducted locally by Yaron Moshel, MD, PhD, and Robert Aiken, MD – determined that adding DCVax-L to standard chemotherapy prolonged patients’ lives by nearly three additional months compared to chemotherapy alone. Dr. Moshel, a neurosurgeon specializing in brain tumors, and Dr. Aiken, a neuro-oncologist, are co-directors of the Gerald J. Glasser Brain Tumor Center.

[OncoJock]

Not that we know of. That would be very big news.

-- OJ

[OncoJock]

I wouldn't put much stock in this part of the story, at the tail end, being timely and accurate. Sounds to me like the reporter is just passing along comments or wishful thinking on the part of the clinical people he spoke to while writing the earlier parts of the story, rather than doing any additional real gumshoe reporting to find out the current status of the application process from someone (presumably at NWBO) who is really in a position to know.

-- OJ